What we do

Our Solutions

Bringing a product to market and sustaining its success requires integrated expertise across every stage of its lifecycle. Our solutions are structured around that journey, connecting capabilities across development, access, compliance, and innovation.

View all Solutions
product development
Product Development
Pre-Clinical to Approval

Accelerate Approval & Launch readiness.

Product Development
Engineering
Engineering
Design & Construction

Engineer Facilities & Ensure GXP readiness.

solution-tabs-icon1
img14
Market & Patient Access
Approval to Access

Prove Value & Secure Access.

solution-tabs-icon2
img15
Product Compliance
Regulatory, Safety & Quality

Ensure Compliance & Patient Safety.

solution-tabs-icon3
img16
Digital & Innovation
Data, Technology & Innovation

Transform Operations & Drive Innovation.

1e406f7c7bc265d40663cf41e862745bcbc49152
In The Spotlight

What's shaping access today

Two regulatory and commercial shifts reshaping European market access, and how PLG is already helping clients navigate them.

Joint Clinical Assessment (JCA)

EMA approval opens the market. A Joint Clinical Assessment fixes your comparators at EU level. We run regulatory strategy, JCA and national pricing as one coordinated programme.

next-arrow
Value-Added Medicines (VAM)

Turning incremental innovation  - new formulations, delivery routes and combinations - into premium, defensible pricing across global markets.

next-arrow
Who We Serve

Application sectors

We provide specialised regulatory and compliance expertise across the core pillars of the life sciences industry, ensuring safety and excellence at every scale.

Biopharma
Biopharma
  • Biopharmaceutical drug development services
  • Regulatory Affairs Services
  • CMC & Quality: Pharma’s Pathway to Excellence
  • Non-clinical and toxicology development
  • Clinical development services
Learn more
Biopharma
Medtech
Medtech
  • Medical device and medtech services
  • MDR & IVDR compliance
  • Quality management systems
Learn more
Medtech
Consumer Health
Consumer Health
  • Self-care product strategy
  • Regulatory and compliance consulting
  • Market access & reimbursement
Learn more
Consumer Health
img3
Startups / Investors
Learn more
Startups / Investors
View all application sectors
Our presence

Global Reach

Operating as a unified global network with specialised localised execution.

  • 50+

    Global offices

  • 150+

    Countries Covered

  • ~1,750

    Experts

  • 10k+

    Submissions/year

MAP
MAP
Join the Team

Where deep expertise meets exciting opportunities.

As part of PLG, you'll join our sector's most trusted advisor: one unified, high-performing team of Advanced Intelligence experts, across Regulatory Affairs, Quality, Safety, Clinical Development, Market Access, Engineering, and Digital & AI, as well as commercial and corporate support functions  partnering with life sciences innovators to bring new medicines and technologies to patients, faster.

120+ Open positions shape
Join the team
Knowledge hub

Expert Insights

Stay informed with the latest PLG news, industry insights, expert perspectives, and thought leadership shaping the future of life sciences and healthcare innovation.

View all expert insights
European JCA: the challenge is not simply having evidence, but knowing how to address each PICO
November 03, 2026
Articles
European JCA: the challenge is not simply having evidence, but knowing how to address each PICO

One of the main challenges of the European Joint Clinical Assessment (JCA) does not lie in preparing the dossier itself. It lies in ensuring that the available evidence can address the questions raised by the different Member States.

next-arrow
“The rarest thing about rare diseases should be their prevalence, not patients' access to appropriate care, innovation and treatment.
October 01, 2026
Articles
“The rarest thing about rare diseases should be their prevalence, not patients' access to appropriate care, innovation and treatment."

More than 300 million people worldwide live with a rare disease. Yet despite remarkable scientific advances, many patients continue to face delayed diagnoses, limited treatment options, and unequal access to innovative therapies.

next-arrow
Your EU Dossier Is Not GCC-Ready: What Sponsors Need to Know in 2026
September 15, 2026
Articles
Your EU Dossier Is Not GCC-Ready: What Sponsors Need to Know in 2026

"Regulatory Compass | Navigating Global Markets" is PLG's ongoing series of expert insights from our regional regulatory affairs teams. Each article draws on direct field experience to help pharmaceutical companies anticipate challenges, make informe...

next-arrow
Stay ahead

Join PLG pulse

One monthly read to keep you informed on what matters in life sciences: expert perspectives, regulatory developments, upcoming events, webinars and more.

Newsroom

News & Press Releases

Stay up to date with PLG's latest news, press releases, and company milestones - from strategic partnerships to key achievements.

View all

One of the main challenges of the European Joint Clinical Assessment (JCA) does not lie in preparing...

arrow

Most Value-Added Medicines don't fail in the lab. They fail at the point where a regulator, an HTA b...

arrow

A sunscreen enquiry can start with a simple question about SPF and end in an adverse event, quality ...

arrow

On 29 September 2026, Lean Lab, the LifeBee format that has brought Life Sciences laboratory profess...

arrow

Two important regulatory developments published this month indicate meaningful progress for CBD as a...

arrow

More than 300 million people worldwide live with a rare disease. Yet despite remarkable scientific a...

arrow

A new study by PLG Market Access experts, published in Global & Regional Health Technology Asses...

arrow

"Regulatory Compass | Navigating Global Markets" is PLG's ongoing series of expert insights from our...

arrow

For many Australian Sponsors, GMP compliance is primarily managed through oversight of their manufac...

arrow

Trust does not appear in the results. It is built long before they are published. A misplaced biolog...

arrow
Our Network

Memberships & Associations